Findings from 11 investigational studies include new data in premenopausal women and comparative analyses of BCI Testing to the 21-gene assay “These data reinforce Hologic’s continued commitment to ...
Previous studies have demonstrated that while some women with early-stage HR+ breast cancer may reduce their risk of recurrence with longer anti-estrogen therapy (10 vs. 5 years), most women do not ...
Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast ...
The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially ...
SAN ANTONIO — The Breast Cancer Index (BCI) gene test, which is usually used to predict the benefit of extended endocrine therapy, could be performed earlier in order to determine whether ...
A new analysis of the Breast Cancer Index (BCI) may help identify women with HR-positive breast cancer who could potentially benefit from shorter or less-intensive treatment. Marie-France Jilderda, MD ...
The Breast Cancer Index (BCI) test assay could help physicians alter their extended endocrine therapy recommendations for patients with hormone receptor (HR)–positive breast cancer and reduce the risk ...
New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration Findings from 11 ...
Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients Completed assessment of more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results